HOME >> MEDICINE >> NEWS
Specialty medical societies offer evidence-based conclusions on inhaled steroid treatment for asthma

(NORTHBROOK, IL, December 9, 2003) - Inhaled corticosteroid (ICS) therapy remains the gold standard of asthma treatment, according to findings from a systematic evidence review released today by the American College of Chest Physicians (ACCP), the American Academy of Allergy, Asthma, and Immunology (AAAAI), and the American College of Allergy, Asthma, and Immunology (ACAAI). Published in the December issue of CHEST, the peer-reviewed journal of the ACCP, the review offers evidence-based conclusions on several prominent risks associated with ICS therapy for the treatment of adult and pediatric asthma.

"ICS therapy has been the gold standard in asthma treatment for 20 years because of its proven effectiveness. However, since the inception of ICS therapy, physicians have been concerned about side effects, particularly in special populations, such as children, women, and the elderly," said lead author Frank T. Leone, MD, MS, FCCP, Thomas Jefferson University, Philadelphia, PA. "After a systematic and accurate review of the proven risks, we can say with confidence that the majority of evidence supports the conclusion that the clinical effectiveness of ICS therapy decidedly outweighs the proven risks."

An expert panel with representatives from the ACCP, the AAAAI, and the ACAAI identified critical questions that impact decisions regarding the use of ICS therapy in relation to the five adult and pediatric risk areas of bone mineral density (BMD), cataracts, glaucoma, growth retardation, and skin thinning. Panel members reviewed 108 asthma studies related to ICS therapy complications and summarized all relevant evidence for each risk area. A consensus statement was provided for each risk area along with a grade to reflect the quantity and quality of evidence supporting each conclusion. Overall, the panel concluded that the benefits associated with ICS use greatly exceed the risks. In regards to the effect of ICS therapy on BMD, the panel stro
'"/>

Contact: Jennifer Stawarz
jstawarz@chestnet.org
847-498-8306
American College of Chest Physicians
8-Dec-2003


Page: 1 2

Related medicine news :

1. Rigorous Evaluation Of "Hospitalist" Model Needed To Determine Impact Of This New Medical Specialty, According To UCSF Health Policy Researchers
2. Advertising by academic medical centers may risk eroding public trust, says study
3. NIH state-of-the-science panel calls for demedicalization of menopause
4. Community care tops medical care at preventing heart disease in black Americans
5. Breakthrough in medical research: New chemotherapy gives hope to brain tumour patients
6. Jefferson Lab medical imager spots breast cancer
7. Society of Hospital Medicine to launch new medical journal
8. LA BioMed medical/research briefs March 2005
9. Promising new strategy for Swedish medical research
10. Flu vaccination benefits people of any age with high-risk medical conditions
11. UCLA study: Nearly a third of drug ads in medical journals contain no references for medical claims

Post Your Comments:
(Date:10/31/2014)... Energy Textiles has recently added a ... is now available online, and Energy Textile is providing ... infrared-active athletic gear over compression gear. , The ... been signed for Under Armour to provide team gear ... years. In light of this decision, Energy Textiles contemplates ...
(Date:10/31/2014)... IL – New research suggests that insomnia is a ... and other unintentional fatal injuries. The results underscore the ... the National Healthy Sleep Awareness Project. , Results show ... a dose-dependent manner with the number of insomnia symptoms ... 2.8 times more likely to die from a fatal ...
(Date:10/31/2014)... New York (PRWEB) October 31, 2014 ... Mineola Eye in Garden City, Long Island and the ... to their medical staff, according to North Shore Eye ... is the Emeritus Acting Chairman of the Department of ... and successful practice in Garden City for more than ...
(Date:10/31/2014)... In an effort to expand services and improve efficiency ... will soon offer orthodontics at his Oral & Maxillofacial Surgery ... , To build upon the high degree of care and ... known for, Dr. Jamali is welcoming an orthodontist that is ... as UCLA, Stanford and UCSF. He added that the new ...
(Date:10/31/2014)... Radiology and EMR Integration , “Surveys ... diagnostic imaging centers but Connectivity is Opportunity,” says ... “Differentiation is critical in all businesses today and ... the intense competition and the downward pressure on ... from the competition by fully integrating with the ...
Breaking Medicine News(10 mins):Health News:Compression Gear--Is There a Better Alternative? 2Health News:Compression Gear--Is There a Better Alternative? 3Health News:Compression Gear--Is There a Better Alternative? 4Health News:Insomnia increases risk of motor vehicle deaths, other fatal injuries 2Health News:William Kasper, MD Garden City Ophthalmologist, Joins Medical Staff at North Shore Eye Care 2Health News:William Kasper, MD Garden City Ophthalmologist, Joins Medical Staff at North Shore Eye Care 3Health News:Oral & Maxillofacial Surgery of New York Adds Orthodontic Patient Services 2Health News:Oral & Maxillofacial Surgery of New York Adds Orthodontic Patient Services 3Health News:Diagnostic Imaging of Salem Expects Growth Partnering with DigitalOne 2
(Date:10/31/2014)... October 30, 2014 ... the addition of the  "Process Validation in the ... offering.      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,Key ... Risk Based Approach to Process Validation for Pharmaceutical ... FDA Process Validation Guidance ...
(Date:10/31/2014)... 31, 2014  Isis Pharmaceuticals, Inc. (NASDAQ: ... , Isis Pharmaceuticals, Third Quarter 2014 Financial Results ... at 11:30 a.m. ET / 8:30 a.m. PTWhere: ... Internet. Simply log onto our website listed above. If ... a replay of the webcast will be available for ...
(Date:10/31/2014)... -- AbbVie (NYSE: ABBV ) today announced ... 30, 2014. "Our third-quarter results ... double-digit growth from HUMIRA and several other key ... in the quarter excluding lipids," said Richard A. ... exceeded our outlook for the quarter and have ...
Breaking Medicine Technology:Process Validation in the US and EU (Workshop, London) 2Process Validation in the US and EU (Workshop, London) 3Process Validation in the US and EU (Workshop, London) 4Webcast Alert: Isis Pharmaceuticals' Third Quarter 2014 Financial Results Conference Call 2Webcast Alert: Isis Pharmaceuticals' Third Quarter 2014 Financial Results Conference Call 3AbbVie Reports Third-Quarter 2014 Financial Results 2AbbVie Reports Third-Quarter 2014 Financial Results 3AbbVie Reports Third-Quarter 2014 Financial Results 4AbbVie Reports Third-Quarter 2014 Financial Results 5AbbVie Reports Third-Quarter 2014 Financial Results 6AbbVie Reports Third-Quarter 2014 Financial Results 7AbbVie Reports Third-Quarter 2014 Financial Results 8AbbVie Reports Third-Quarter 2014 Financial Results 9AbbVie Reports Third-Quarter 2014 Financial Results 10AbbVie Reports Third-Quarter 2014 Financial Results 11AbbVie Reports Third-Quarter 2014 Financial Results 12AbbVie Reports Third-Quarter 2014 Financial Results 13AbbVie Reports Third-Quarter 2014 Financial Results 14AbbVie Reports Third-Quarter 2014 Financial Results 15AbbVie Reports Third-Quarter 2014 Financial Results 16AbbVie Reports Third-Quarter 2014 Financial Results 17AbbVie Reports Third-Quarter 2014 Financial Results 18AbbVie Reports Third-Quarter 2014 Financial Results 19AbbVie Reports Third-Quarter 2014 Financial Results 20AbbVie Reports Third-Quarter 2014 Financial Results 21AbbVie Reports Third-Quarter 2014 Financial Results 22AbbVie Reports Third-Quarter 2014 Financial Results 23AbbVie Reports Third-Quarter 2014 Financial Results 24
Cached News: